跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
SILIQ - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
SILIQ
Authorized
STANDARD
SILIQ
bausch health, canada inc.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
da87303c0084197e
Company
bausch health, canada inc.
Type
Standard
Approval Details
Approval Id
da87303c0084197e
Drug Approval Canada Name
SILIQ
Product Name
SILIQ
Status
Marketed
Status Date
2019-06-07
Original Market Date
2018-07-05
Din
02473623
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Schedule D , Prescription
Ahfs
84:06.28
Atc Original
L04AC12 BRODALUMAB
Atc Name
l 04 ac 12
Aig Number
0160070001
Company Name
bausch health, canada inc.
Company Address
2150 Boul. St-Elzear Ouest, Laval, Quebec, Canada, H7L 4A8
Active Ingredients
BRODALUMAB
210 MG / 1.5 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
da87303c0084197e
Type
Standard
Back to Health Canada Approvals